Docking Study to Predict the Efficacy of Phosphatidylinositol 3-Kinase α Inhibitors
The phosphatidylinositol 3-kinase (PI3K) family comprises lipid kinases that cross-link signals between living cells and their surroundings. PI3Ks are classified into several groups and isoforms with specific characteristics and functions. Genes encoding PI3Ks are mutated in several types of cancer, and their isoforms have varying capacity in promoting cell signaling and cancer progression. Many compounds have been introduced as PI3Kα inhibitors, but not all of them have the same inhibitory effects. For successful PI3K-related biomedical experiments, it is vital to select the most specific and potent compounds with the highest inhibitory effects for targeting this kinase. In this study, we investigate 28 well-recognized PI3Kα inhibitors through predicting their specificity and potency using the docking software AutoDock Vina. Our data showed that PF 05212384 had the highest docking score (−9.2 kcal/mol), and 3-methyladenine had the lowest docking score (−4.8 kcal/mol). Our data also showed different types of interactions and bonds formed between the inhibitors and protein residues. In conclusion, PF 05212384 and AZD 6482 compounds are the best candidates for targeting PI3Kα. In addition to hydrophobic interactions in the PI3Kα binding pocket, the formation of hydrogen bonds between these inhibitors and binding pocket residues was confirmed.
Amzel, L.M., Huang, C.H., Mandelker, D., Lengauer, C., Gabelli, S.B. and Vogelstein, B., 2008. Structural comparisons of class I phosphoinositide 3-kinases. Nature Reviews Cancer, 8(9), pp.665-669.
Auger, K.R., Serunian, L.A., Soltoff, S.P., Libby, P. and Cantley, L.C., 1989. PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell, 57(1), pp.167-175.
Bader, A.G., Kang, S., Zhao, L. and Vogt, P.K., 2005. Oncogenic PI3K deregulates transcription and translation. Nature Reviews Cancer, 5(12), pp.921-929.
Chalhoub, N. and Baker, S.J., 2009. PTEN and the PI3-Kinase Pathway in Cancer. Annual Review of Pathology: Mechanisms of Disease, 4(1), pp.127-150.
Dassault Systèmes., 2016. Discovery Studio Modeling Environment (Version 4.1). Dassault Systèmes, San Diego.
Dudu, V., Able, R.A. Jr., Rotari, V., Kong, Q. and Vazquez, M., 2012. Role of epidermal growth factor-triggered PI3K/Akt signaling in the migration of medulloblastoma-derived cells. Cellular and Molecular Bioengineering, 5(4), pp.502-413.
Echeverria, I., Liu, Y., Gabelli, S. B. and Amzel, L.M., 2015. Oncogenic mutations weaken the interactions that stabilize the p110alpha-p85alpha heterodimer in phosphatidylinositol 3-kinase alpha. FEBS J, 282(18), pp.3528-3542.
Engelman, J.A., Luo, J. and Cantley, L.C., 2006. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews Genetics, 7, p.606.
Fruman, D.A., Meyers, R.E. and Cantley, L.C., 1998. Phosphoinositide kinases. Annual Review of Biochemistry, 67, pp.481-507.
Gilliland, G., Berman, H.M., Weissig, H., Shindyalov, I.N., Westbrook, J., Bourne, P.E. and Feng, Z., 2000. The protein data bank. Nucleic Acids Res, 28(1), pp.235-242.
Hancock, J.T., 2010. Cell Signalling. 3rd ed. Oxford University Press, Oxford, New York.
Hausler, P., Papoff, G., Eramo, A., Reif, K., Cantrell, D.A. and Ruberti, G., 1998. Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B. European Journal of Immunology, 28(1), pp.57-69.
Hollander, M.C., Blumenthal, G.M. and Dennis, P.A., 2011. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nature Reviews Cancer, 11(4), pp.289-301.
Jaghoori, M.M., Bleijlevens, B. and Olabarriaga, S.D., 2016. 1001 Ways to run autodock vina for virtual screening. Journal of Computer-Aided Molecular Design, 30(3), pp.237-249.
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J. and Waterfield, M.D., 2001. Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis, and cancer. Annual Review of Cell and Developmental Biology, 17, pp.615-675.
Kawade, V.S., Satpute, P.S., Dhulap, S.A. and Gurjar, S., 2018. Therapeutic potential of PI3K/Akt/mTOR signalling pathway: Effective combination therapy for cancer. Indian Journal of Pharmaceutical Sciences, 80(4), pp.
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S. and Bolton, E.E., 2019. PubChem 2019 update: Improved access to chemical data. Nucleic Acids Res, 47(D1), pp.D1102-D1109.
Laurino, L., Wang, X.X., de la Houssaye, B.A., Sosa, L., Dupraz, S., Cáceres, A., Quiroga, S., 2005. PI3K activation by IGF-1 is essential for the regulation of membrane expansion at the nerve growth cone. Journal of Cell Science, 118(16), pp.3653-3662.
Le, P.T., Cheng, H., Ninkovic, S., Plewe, M., Huang, X., Wang, H. and Zhang, E., 2012. Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kalpha and mTOR. Bioorganic and Medicinal Chemistry Letters, 22(15), pp.5098-5103.
Liu, P., Cheng, H., Roberts, T.M. and Zhao, J.J., 2009. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews Drug Discovery, 8(8), pp.627-644.
Luo, J., Manning, B.D. and Cantley, L.C., 2003. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell, 4(4), pp.257-262.
Mandelker, D., Gabelli, S.B., Schmidt-Kittler, O., Zhu, J., Cheong, I., Huang, C.H. and Amzel, L.M., 2009. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proceedings of the National Academy of Sciences of the United States of America, 106(40), pp.16996-17001.
Mangone, F.R., Bobrovnitchaia, I.G., Salaorni, S., Manuli, E. and Nagai, M.A., 2012. PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. Clinics, 67(11), pp.1285-1290.
MGLTools., 2017. Molecular Graphics Laboratory Tools. Available from: http:// www.mgltools.scripps.edu. [Last accessed on 2017 Aug 01].
Nacht, M., Qiao, L., Sheets, M.P., St Martin, T., Labenski, M., Mazdiyasni, H. and Singh, J., 2013. Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kalpha. Journal of Medicinal Chemistry, 56(3), pp.712-721.
O’Boyle, N.M., Banck, M., James, C.A., Morley, C., Vandermeersch, T. and Hutchison, G.R., 2011. Open Babel: An open chemical toolbox. Journal of Cheminformatics, 3(1), p.33.
Okkenhaug, K. and Vanhaesebroeck, B., 2003. PI3K in lymphocyte development, differentiation and activation. Nature Reviews Immunology, 3, p.317.
PerkinElmer., 2009. ChemDraw Professional. Available from: http:// www.cambridgesoft.com/Ensemble_for_Chemistry/ChemDraw/ ChemDrawProfessional/Default.aspx. [Last accessed on 2017 Jul 01].
Perryman, A.L., Santiago, D.N., Forli, S., Santos-Martins, D. and Olson, A.J., 2014. Virtual screening with autodock vina and the common pharmacophore engine of a low diversity library of fragments and hits against the three allosteric sites of HIV integrase: Participation in the SAMPL4 protein ligand binding challenge. Journal of Computer-Aided Molecular Design, 28(4), pp.429-441.
Peso, L.D., González-Garcı́a, M., Page, C., Herrera, R. and Nuñez, G., 1997. Interleukin-3-induced phosphorylation of BAD through the protein kinase akt. Science, 278(5338), pp.687-689.
Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C. and Ferrin, T.E., 2004. UCSF Chimera--a visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25(13), pp.1605-1612.
Sabbah, D.A., Simms, N.A., Brattain, M.G., Vennerstrom, J.L. and Zhong, H., 2012. Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases. Bioorganic and Medicinal Chemistry Letters, 22(2), pp.876-880.
Sabbah, D.A., Vennerstrom, J.L. and Zhong, H., 2010. Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases. Journal of Chemical Information and Modeling, 50(10), pp.1887-1898.
Sali, A. and Blundell, T.L., 1993. Comparative protein modelling by satisfaction of spatial restraints. Journal of Molecular Biology, 234(3), pp.779-815.
Samuels, Y. and Waldman, T., 2010. Oncogenic mutations of PIK3CA in human cancers. Current Topics in Microbiology and Immunology, 347, pp.21-41.
Schmidt, H., Kulasinghe, A., Allcock, R.J.N., Tan, L.Y., Mokany, E., Kenny, L. and Punyadeera, C., 2018. A Pilot study to non-invasively track PIK3CA mutation in head and neck cancer. Diagnostics, 8(4), p.79.
Singh, P. and Bast, F., 2013. Multitargeted molecular docking study of plant-derived natural products on phosphoinositide-3 kinase pathway components. Medicinal Chemistry Research, 23(4), pp.1690-1700.
Songyang, Z., Shoelson, S.E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W.G., King, F., Roberts, T., Ratnofsky, S. and Lechleider, R.J., 1993. SH2 domains recognize specific phosphopeptide sequences. Cell, 72(5), pp.767-778.
Trott, O. and Olson, A.J., 2010. Autodock vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), pp.455-461.
Ueki, K., Fruman, D.A., Brachmann, S.M., Tseng, Y.H., Cantley, L.C. and Kahn, C.R., 2002. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Molecular and Cellular Biology, 22(3), p.965.
Vanhaesebroeck, B., Leevers, S.J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P.C. and Waterfield, M.D., 2001. Synthesis and function of 3-phosphorylated inositol lipids. Annual Review of Biochemistry, 70, pp.535-602.
Vanhaesebroeck, B., Vogt, P.K. and Rommel, C., 2010. PI3K: From the bench to the clinic and back. Current Topics in Microbiology and Immunology, 347, pp.1-19.
Vivanco, I. and Sawyers, C.L., 2002. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Reviews Cancer, 2(7), pp.489-501.
Wang, W.F., Xie, Y., Zhou, Z.H., Qin, Z.H., Wu, J.C. and He, J.K., 2013. PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients. Acta Pharmacologica Sinica, 34(12), pp.1560-1567.
Wang, X., Ding, J. and Meng, L.H., 2015. PI3K isoform-selective inhibitors: Next-generation targeted cancer therapies. Acta Pharmacologica Sinica, 36(10), pp.1170-1176.
Whitman, M., Downes, C.P., Keeler, M., Keller, T. and Cantley, L., 1988. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature, 332(6165), pp.644-646.
Copyright (c) 2019 Mahmoud A. Chawsheen, Hazem A. Al-Bustany
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License [CC BY-NC-SA 4.0] that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).